PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: DVS SR
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 283
- Registration Number
- NCT01371708
- Locations
- π¨π±
Biomedica Research Group, Santiago, Region Metropolitana, Chile
πΊπΈDiscovery and Wellness Center for Children/University Hospitals Case Medical Center, Cleveland, Ohio, United States
πΊπΈPharmasite Research, Inc, Baltimore, Maryland, United States
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: DVS SR
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 269
- Registration Number
- NCT01371721
- Locations
- πΊπΈ
Dedicated Clinical Research, Goodyear, Arizona, United States
πΊπΈHarmonex Neuroscience Research, Inc., Dothan, Alabama, United States
πΊπΈAmedica Research Institute, Incorporated, Hialeah, Florida, United States
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 340
- Registration Number
- NCT01372150
- Locations
- πΊπΈ
Winter Park Memorial Hospital, Winter Park, Florida, United States
πΊπΈAtlanta Center for Medical Research, Atlanta, Georgia, United States
π²π½CIT - Neuropsique, S.C., Monterrey, Nuevo LEON, Mexico
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 363
- Registration Number
- NCT01371734
- Locations
- πΊπΈ
Institute of Living/Hartford Hospital, Hartford, Connecticut, United States
πΊπΈInstitute of Living, Hartford, Connecticut, United States
πΊπΈPharmasite Research Inc, Baltimore, Maryland, United States
A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
- Conditions
- Community-Acquired Bacterial PneumoniaLung Infection of Individual Not Recently Hospitalized
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 848
- Registration Number
- NCT01371838
- Locations
- π»π³
Research Site, Hochiminh, Vietnam
A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: PF-05190457 or Placebo
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT01372163
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1510
- Registration Number
- NCT01370356
- Locations
- π¦πΊ
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
π¨π¦Office of Dr. Ronald Collette, Burnaby, British Columbia, Canada
π¬π§The Alverton Practice, Penzance, Cornwall, United Kingdom
Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2011-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT01369836
- Locations
- πΊπΈ
Pfizer Investigational Site, Glendale, California, United States
Single Dose Study Of The Effect Of Cyclosporine On The Pharmacokinetics Of PF-04991532 In Health Volunteers
- Conditions
- HealthyDrug Interaction
- Interventions
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2011-09-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01370343
- Locations
- π§πͺ
Pfizer Investigational Site, Bruxelles, Belgium
Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532
- First Posted Date
- 2011-06-09
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT01369602
- Locations
- πΊπΈ
Pfizer Investigational Site, DeLand, Florida, United States